Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Allogeneic T-cell Progenitors
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Smart Immune
Deal Size : Undisclosed
Deal Type : Partnership
Smart Immune & CELLforCURE by SEQENS Partner for SMART101 Clinical Manufacturing
Details : The partnership aims to advance the clinical development of SMART101 an innovative therapy for patients with acute leukemia or primary immunodeficiencies (PID), in the EU and the US.
Brand Name : SMART101
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : Allogeneic T-cell Progenitors
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Smart Immune
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Biophytis
Deal Size : Undisclosed
Deal Type : Agreement
Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound
Details : The agreement aims for the production of the active compound in Sarconeos (20-hydroxyecdysone), Biophytis' main drug candidate developed for three indications, severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy.
Brand Name : Sarconeos
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 18, 2023
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Biophytis
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
KEY PRODUCTS
Reset All
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.